{"id":"oral-immediate-released-morphine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Constipation"},{"rate":"20-30","effect":"Nausea"},{"rate":"20-30","effect":"Drowsiness"},{"rate":"10-20","effect":"Dizziness"},{"rate":"10-15","effect":"Vomiting"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Dependence/tolerance"}]},"_chembl":{"chemblId":"CHEMBL5665374","moleculeType":null,"molecularWeight":"285.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Morphine is a mu-opioid receptor agonist that crosses the blood-brain barrier and acts on opioid receptors in the brain and spinal cord. This binding modulates pain signal transmission and produces analgesic effects. It is commonly used for moderate to severe pain management, particularly in cancer patients.","oneSentence":"Morphine binds to opioid receptors in the central nervous system to reduce pain perception and provide analgesia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:42.406Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer pain in patients with advanced malignancy"},{"name":"Moderate to severe acute and chronic pain"}]},"trialDetails":[{"nctId":"NCT02824276","phase":"PHASE1","title":"Sensory Effects of Oral Opioid Treatment in Patients With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-01-06","conditions":"Low Back Pain","enrollment":35},{"nctId":"NCT05006079","phase":"PHASE2","title":"Opioid/Benzodiazepine Polydrug Abuse: Aim 3","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2024-03-13","conditions":"Opioid Abuse, Benzodiazepine Abuse, Polysubstance Abuse","enrollment":24},{"nctId":"NCT04110665","phase":"PHASE4","title":"Multimodal Analgesia Strategies After Major Shoulder Ambulatory Surgery","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2017-09-01","conditions":"Tendon Injuries","enrollment":92},{"nctId":"NCT04785768","phase":"PHASE3","title":"IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2021-07-01","conditions":"Cancer Pain","enrollment":1372},{"nctId":"NCT05846451","phase":"EARLY_PHASE1","title":"Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints","status":"RECRUITING","sponsor":"Washington State University","startDate":"2023-06-01","conditions":"Herbal Interaction","enrollment":16},{"nctId":"NCT06212622","phase":"","title":"Is the Rate of Early Mobilisation in Hip Fracture Patients Using Alfentanil Better Than Standard Opioid Analgesia?","status":"COMPLETED","sponsor":"NHS Lothian","startDate":"2024-03-04","conditions":"Hip Injuries, Hip Fractures, Pain","enrollment":64},{"nctId":"NCT05571345","phase":"PHASE1","title":"A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2022-10-05","conditions":"Recreational Drug Use","enrollment":32},{"nctId":"NCT04310579","phase":"PHASE1","title":"Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-06-15","conditions":"Hypercapnia, Ventilatory Depression","enrollment":55},{"nctId":"NCT04030442","phase":"PHASE1","title":"Cannabidiol, Morphine, Pain","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2019-05-01","conditions":"CBD, Chronic Pain","enrollment":40},{"nctId":"NCT04087317","phase":"NA","title":"Vaginal Postpartum Pain Management Protocol Comparison","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2020-06-01","conditions":"Pain, Post Partum Depression, Opioid Use","enrollment":200},{"nctId":"NCT04808531","phase":"PHASE3","title":"NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers","status":"UNKNOWN","sponsor":"Medlab Clinical","startDate":"2023-11","conditions":"Cancer Related Pain","enrollment":360},{"nctId":"NCT02687451","phase":"PHASE3","title":"Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects","status":"TERMINATED","sponsor":"Endo Pharmaceuticals","startDate":"2016-04","conditions":"Post-Operative Pain, Acute Pain","enrollment":28},{"nctId":"NCT01210352","phase":"PHASE3","title":"Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2010-12-13","conditions":"Post Operative Pain","enrollment":61},{"nctId":"NCT03564548","phase":"PHASE2","title":"Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain","status":"UNKNOWN","sponsor":"Tetra Bio-Pharma","startDate":"2021-05-26","conditions":"Cancer, Breakthrough Cancer Pain","enrollment":20},{"nctId":"NCT04234516","phase":"PHASE4","title":"Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder","status":"WITHDRAWN","sponsor":"New York State Psychiatric Institute","startDate":"2020-01-20","conditions":"Opioid-use Disorder, Suicidal Ideation","enrollment":""},{"nctId":"NCT04243954","phase":"PHASE2","title":"Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2020-04-10","conditions":"Cancer Pain","enrollment":95},{"nctId":"NCT04533243","phase":"PHASE3","title":"Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2020-09-01","conditions":"Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naive","enrollment":209},{"nctId":"NCT03275012","phase":"PHASE2","title":"Efficacy and Safety Study of Gabapentin as add-on to Morphine in Paediatric Patients Affected by Chronic Pain","status":"WITHDRAWN","sponsor":"Pharmaceutical Research Management srl","startDate":"2017-04-04","conditions":"Chronic Pain","enrollment":""},{"nctId":"NCT03824834","phase":"PHASE2","title":"Morphine to Maximize the Benefits of Exercise Training in COPD or ILD and Persistent Breathlessness","status":"UNKNOWN","sponsor":"Dennis Jensen, Ph.D.","startDate":"2019-08-06","conditions":"Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease","enrollment":40},{"nctId":"NCT02198924","phase":"PHASE4","title":"Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2014-12","conditions":"Pain, Inflammation","enrollment":246},{"nctId":"NCT03314792","phase":"PHASE4","title":"Effects of Tapentadol Versus Oxycodone After Hysterectomy.","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2017-12-04","conditions":"Pain, Postoperative, Pain Uterus, Pain, Acute","enrollment":86},{"nctId":"NCT00743587","phase":"PHASE1","title":"A Study To Assess The Ability Of Tramadol, Naproxen And Oxycodone To Affect The Pain Thresholds Of Patients With Osteoarthritis Of The Thumb","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Osteoarthritis Thumbs","enrollment":36},{"nctId":"NCT01675622","phase":"PHASE3","title":"Immediate-Release Oxycodone Capsules Study in Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2011-01","conditions":"Cancer","enrollment":242},{"nctId":"NCT03137030","phase":"PHASE1","title":"A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults","status":"WITHDRAWN","sponsor":"Grünenthal GmbH","startDate":"2017-09","conditions":"Opioid-Related Disorders, Pain, Acute, Pain, Postoperative","enrollment":""},{"nctId":"NCT03137017","phase":"PHASE1","title":"A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults","status":"WITHDRAWN","sponsor":"Grünenthal GmbH","startDate":"2017-09","conditions":"Opioid-Related Disorders, Pain, Acute, Pain, Postoperative","enrollment":""},{"nctId":"NCT00158184","phase":"PHASE2","title":"Prescription Opioid Effects in Abusers Versus Non-Abusers","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2004-06","conditions":"Opioid-Related Disorders, Substance-Related Disorders","enrollment":27},{"nctId":"NCT01871285","phase":"PHASE2","title":"Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film","status":"COMPLETED","sponsor":"BioDelivery Sciences International","startDate":"2013-06","conditions":"Pain","enrollment":39},{"nctId":"NCT02773316","phase":"PHASE1","title":"Study to Assess Pharmacokinetic (PK), Bioavailability & Food Effect of MR902 Compared With Immediate Release (IR) Morphine Sulphate Oral Solution","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2015-09","conditions":"Opioid Substitution Treatment","enrollment":84},{"nctId":"NCT01946555","phase":"","title":"Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2013-09","conditions":"Tumor, Cancer Pain, Breakthrough Cancer Pain","enrollment":150},{"nctId":"NCT01986283","phase":"PHASE1","title":"Abuse Potential Study of PF-00345439","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2013-11","conditions":"Opioid Users","enrollment":67},{"nctId":"NCT02206607","phase":"PHASE1","title":"Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":39},{"nctId":"NCT00573937","phase":"PHASE2","title":"Methadone Versus Morphine for Cancer-Related Pain","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2007-08","conditions":"Neoplasms, Pain","enrollment":1},{"nctId":"NCT00580294","phase":"NA","title":"A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2007-11","conditions":"Pain","enrollment":12},{"nctId":"NCT01672112","phase":"PHASE4","title":"Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2012-07","conditions":"Postcraniotomy Pain","enrollment":40},{"nctId":"NCT00201539","phase":"PHASE3","title":"Double Bedtime Dosing During Immediate-release Morphine Administration to Cancer Patients","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2002-04","conditions":"Cancer","enrollment":19},{"nctId":"NCT00410540","phase":"PHASE3","title":"A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain, Analgesics, Opioid","enrollment":202},{"nctId":"NCT00125801","phase":"PHASE3","title":"The Pain Pen for Breakthrough Cancer Pain","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2005-08","conditions":"Neoplasms, Pain","enrollment":50},{"nctId":"NCT00390312","phase":"PHASE2","title":"Efficacy and Safety of Intranasal Morphine for Pain After Third Molar Extraction","status":"COMPLETED","sponsor":"Javelin Pharmaceuticals","startDate":"2001-09","conditions":"Post-Operative Pain, Third Molar Extraction","enrollment":225}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oral immediate-released morphine","genericName":"Oral immediate-released morphine","companyName":"Fujian Cancer Hospital","companyId":"fujian-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral immediate-release morphine is used to treat pain, including post-operative pain, hip injuries, and hip fractures. Its mechanism of action involves interacting with opioid receptors in the brain, although the exact details of this interaction are not specified in the provided facts.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}